Heart Attack Diagnostics Market
Heart Attack Diagnostics Market Forecasts to 2032 – Global Analysis By Product (Instruments, Consumables, Software, Services), Test Type, Biomarker, Imaging Modality, Diagnosis Method, Age Group, Application, End User, and By Geography
According to Stratistics MRC, the Global Heart Attack Diagnostics Market is accounted for $12.5 billion in 2025 and is expected to reach $21.8 billion by 2032 growing at a CAGR of 8.2% during the forecast period. Heart Attack Diagnostics are medical procedures, tests, and devices used to detect and confirm myocardial infarction, a condition caused by restricted blood flow to the heart. These diagnostics include blood tests for cardiac biomarkers, electrocardiograms (ECG), imaging modalities, and stress tests. They help evaluate heart damage, identify blockages, and guide treatment decisions. Accurate and timely heart attack diagnostics are critical for reducing mortality, improving patient outcomes, and preventing complications related to cardiac events.
According to the World Heart Report, cardiovascular diseases continue to affect more than 500 million people across the globe.
Market Dynamics:
Driver:
Increasing adoption of point-of-care testing devices
The market for heart attack diagnostics is spurred by the rising adoption of point-of-care (POC) testing devices, which enable rapid and accurate detection of cardiac biomarkers at bedside or emergency settings. These devices reduce turnaround times significantly, ensuring timely clinical intervention and improved patient outcomes. Growing emphasis on decentralized healthcare and emergency response efficiency strengthens their adoption globally. Furthermore, technological advancements in portable diagnostic platforms support broader accessibility, making POC testing a pivotal driver in the heart attack diagnostics landscape.
Restraint:
Limited access to diagnostics in rural regions
A significant restraint hindering market growth is the limited access to advanced diagnostic facilities in rural and remote regions. Infrastructure gaps, lack of trained healthcare professionals, and high equipment costs restrict adoption of advanced diagnostic tools in these areas. Consequently, delayed detection of cardiac events leads to poor treatment outcomes, widening healthcare disparities. While urban centers benefit from rapid technological adoption, rural healthcare systems continue to face challenges. This disparity slows overall market penetration and limits equitable diagnostic availability.
Opportunity:
Integration of AI-driven diagnostic platforms
The integration of artificial intelligence (AI) into diagnostic systems presents a promising opportunity for the heart attack diagnostics market. AI-enabled platforms enhance interpretation of complex imaging and biomarker data, enabling faster and more accurate detection of myocardial infarction. Growing investments in digital health and predictive analytics support AI adoption across hospital networks. Additionally, AI-driven decision support tools aid clinicians in triage and treatment planning. As AI technologies mature, their integration enhances precision diagnostics, ultimately revolutionizing cardiac care pathways worldwide.
Threat:
Risk of misdiagnosis affecting clinical trust levels
Despite technological advancements, the risk of misdiagnosis remains a critical threat in the heart attack diagnostics market. False positives or negatives in biomarker assays or imaging tests can undermine physician confidence and negatively impact patient safety. Such occurrences may lead to unnecessary treatments or missed interventions, eroding trust in diagnostic systems. Additionally, concerns over variability in test accuracy across different platforms intensify this threat. Sustained clinical validation and standardization are therefore crucial to mitigate risks and preserve diagnostic credibility.
Covid-19 Impact:
The COVID-19 pandemic significantly disrupted the heart attack diagnostics market, with hospitals prioritizing COVID care and delaying elective cardiac testing. Patient reluctance to visit healthcare facilities further reduced diagnostic volumes. However, the crisis accelerated adoption of point-of-care testing and telehealth-driven cardiac monitoring solutions. Post-pandemic recovery has seen renewed emphasis on early cardiac diagnostics, with healthcare systems investing in resilient diagnostic infrastructure. Consequently, COVID-19 served as both a short-term setback and a long-term catalyst for innovation and decentralization in cardiac diagnostics.
The instruments segment is expected to be the largest during the forecast period
The instruments segment is expected to account for the largest market share during the forecast period, owing to their widespread use in hospitals, diagnostic laboratories, and emergency care centers. Instruments such as analyzers, imaging devices, and biomarker detection systems form the backbone of cardiac diagnostics, ensuring accurate and timely assessments. Growing demand for technologically advanced and automated diagnostic instruments further consolidates their dominance. Moreover, continuous innovation in imaging modalities and biomarker platforms reinforces the instruments segment as the market’s leading contributor.
The echocardiogram segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the echocardiogram segment is predicted to witness the highest growth rate, impelled by its non-invasive nature and ability to provide real-time cardiac imaging. The increasing prevalence of cardiovascular diseases and preference for ultrasound-based diagnostics fuel demand. Advancements in 3D and portable echocardiography systems enhance clinical accuracy and accessibility. Additionally, echocardiograms are becoming integral in emergency and outpatient settings for rapid heart function assessment. This convergence of innovation and adoption establishes echocardiography as the fastest-growing diagnostic segment.
Region with largest share:
During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by its expanding patient pool, rising cardiovascular disease prevalence, and growing healthcare infrastructure. Increasing government initiatives to strengthen early disease detection systems further enhance adoption. Moreover, the presence of cost-effective diagnostic solutions in emerging economies boosts accessibility. Rapid urbanization and lifestyle changes exacerbate cardiac risk factors, fueling diagnostic demand. Collectively, these elements position Asia Pacific as the leading regional market in heart attack diagnostics.
Region with highest CAGR:
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to advanced healthcare infrastructure, high diagnostic awareness, and rapid technology adoption. Strong presence of leading diagnostic companies and extensive R&D investments accelerate innovation in cardiac testing solutions. Favorable reimbursement frameworks support market penetration of advanced diagnostics. Additionally, growing demand for precision diagnostics and digital health integration amplifies adoption. As cardiovascular burden continues to rise, North America emerges as the fastest-expanding regional market.
Key players in the market
Some of the key players in Heart Attack Diagnostics Market include Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche Ltd., GE Healthcare, Philips Healthcare, Bio-Rad Laboratories, Beckman Coulter (Danaher), Thermo Fisher Scientific Inc., Qiagen N.V., Randox Laboratories, Ortho Clinical Diagnostics, Becton, Dickinson and Company, CardioDx Inc., Biomerica Inc., Luminex Corporation, BioMerieux SA, Nova Biomedical, Nihon Kohden Corporation, Response Biomedical Corporation, and Critical Diagnostics.
Key Developments:
In May 2025, Roche Diagnostics (F. Hoffmann-La Roche Ltd) received FDA 510(k) clearance for an enhanced version of its Elecsys® Troponin T high-sensitivity test, aimed at providing even more precise risk stratification for patients presenting with chest pain in the emergency department.
In April 2025, Siemens Healthineers announced the U.S. launch of its Atellica® CI1900 Integrated Solution, which combines core laboratory and cardiac testing to deliver a consolidated troponin result from a single platform, improving workflow efficiency for heart attack diagnosis.
In March 2025, Abbott Laboratories initiated a major clinical study across 100 sites in the U.S. and Europe to expand the clinical claims for its Alinity i High-Sensitivity Troponin-I assay, focusing on rapid rule-out protocols to help reduce emergency room overcrowding.
Products Covered:
• Instruments
• Consumables
• Software
• Services
Test Types Covered:
• Electrocardiogram (ECG)
• Blood Tests
• Echocardiogram
• Coronary Angiography
Biomarkers Covered:
• Troponin
• Creatine Kinase-MB (CK-MB)
• Myoglobin
• C-Reactive Protein (CRP)
• Brain Natriuretic Peptide (BNP)
Imaging Modalities Covered:
• Echocardiography
• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Nuclear Imaging
• X-ray
Diagnosis Methods Covered:
• Laboratory Testing
• Imaging Testing
• Point-of-Care Testing
Age Groups Covered:
• Below 40 Years
• Above 60 Years
Applications Covered:
• Emergency Diagnosis
• Risk Assessment
• Therapy Monitoring
• Research Applications
End Users Covered:
• Hospitals
• Diagnostic Centers
• Ambulatory Surgical Centers
• Research Laboratories
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Heart Attack Diagnostics Market, By Product
5.1 Introduction
5.2 Instruments
5.3 Consumables
5.4 Software
5.5 Services
6 Global Heart Attack Diagnostics Market, By Test Type
6.1 Introduction
6.2 Electrocardiogram (ECG)
6.3 Blood Tests
6.4 Echocardiogram
6.5 Coronary Angiography
7 Global Heart Attack Diagnostics Market, By Biomarker
7.1 Introduction
7.2 Troponin
7.3 Creatine Kinase-MB (CK-MB)
7.4 Myoglobin
7.5 C-Reactive Protein (CRP)
7.6 Brain Natriuretic Peptide (BNP)
8 Global Heart Attack Diagnostics Market, By Imaging Modality
8.1 Introduction
8.2 Echocardiography
8.3 Computed Tomography (CT)
8.4 Magnetic Resonance Imaging (MRI)
8.5 Nuclear Imaging
8.6 X-ray
9 Global Heart Attack Diagnostics Market, By Diagnosis Method
9.1 Introduction
9.2 Laboratory Testing
9.3 Imaging Testing
9.4 Point-of-Care Testing
10 Global Heart Attack Diagnostics Market, By Age Group
10.1 Introduction
10.2 Below 40 Years
10.3 Above 60 Years
11 Global Heart Attack Diagnostics Market, By Application
11.1 Introduction
11.2 Emergency Diagnosis
11.3 Risk Assessment
11.4 Therapy Monitoring
11.5 Research Applications
12 Global Heart Attack Diagnostics Market, By End User
12.1 Introduction
12.2 Hospitals
12.3 Diagnostic Centers
12.4 Ambulatory Surgical Centers
12.5 Research Laboratories
13 Global Heart Attack Diagnostics Market, By Geography
13.1 Introduction
13.2 North America
13.2.1 US
13.2.2 Canada
13.2.3 Mexico
13.3 Europe
13.3.1 Germany
13.3.2 UK
13.3.3 Italy
13.3.4 France
13.3.5 Spain
13.3.6 Rest of Europe
13.4 Asia Pacific
13.4.1 Japan
13.4.2 China
13.4.3 India
13.4.4 Australia
13.4.5 New Zealand
13.4.6 South Korea
13.4.7 Rest of Asia Pacific
13.5 South America
13.5.1 Argentina
13.5.2 Brazil
13.5.3 Chile
13.5.4 Rest of South America
13.6 Middle East & Africa
13.6.1 Saudi Arabia
13.6.2 UAE
13.6.3 Qatar
13.6.4 South Africa
13.6.5 Rest of Middle East & Africa
14 Key Developments
14.1 Agreements, Partnerships, Collaborations and Joint Ventures
14.2 Acquisitions & Mergers
14.3 New Product Launch
14.4 Expansions
14.5 Other Key Strategies
15 Company Profiling
15.1 Abbott Laboratories
15.2 Siemens Healthineers
15.3 F. Hoffmann-La Roche Ltd.
15.4 GE Healthcare
15.5 Philips Healthcare
15.6 Bio-Rad Laboratories Inc.
15.7 Beckman Coulter (Danaher Corporation)
15.8 Thermo Fisher Scientific Inc.
15.9 Qiagen N.V.
15.10 Randox Laboratories Ltd.
15.11 Ortho Clinical Diagnostics
15.12 Becton, Dickinson and Company (BD)
15.13 CardioDx Inc.
15.14 Biomerica Inc.
15.15 Luminex Corporation
15.16 BioMerieux SA
15.17 Nova Biomedical
15.18 Nihon Kohden Corporation
15.19 Response Biomedical Corporation
15.20 Critical Diagnostics
List of Tables
1 Global Heart Attack Diagnostics Market Outlook, By Region (2024-2032) ($MN)
2 Global Heart Attack Diagnostics Market Outlook, By Product (2024-2032) ($MN)
3 Global Heart Attack Diagnostics Market Outlook, By Instruments (2024-2032) ($MN)
4 Global Heart Attack Diagnostics Market Outlook, By Consumables (2024-2032) ($MN)
5 Global Heart Attack Diagnostics Market Outlook, By Software (2024-2032) ($MN)
6 Global Heart Attack Diagnostics Market Outlook, By Services (2024-2032) ($MN)
7 Global Heart Attack Diagnostics Market Outlook, By Test Type (2024-2032) ($MN)
8 Global Heart Attack Diagnostics Market Outlook, By Electrocardiogram (ECG) (2024-2032) ($MN)
9 Global Heart Attack Diagnostics Market Outlook, By Blood Tests (2024-2032) ($MN)
10 Global Heart Attack Diagnostics Market Outlook, By Echocardiogram (2024-2032) ($MN)
11 Global Heart Attack Diagnostics Market Outlook, By Coronary Angiography (2024-2032) ($MN)
12 Global Heart Attack Diagnostics Market Outlook, By Biomarker (2024-2032) ($MN)
13 Global Heart Attack Diagnostics Market Outlook, By Troponin (2024-2032) ($MN)
14 Global Heart Attack Diagnostics Market Outlook, By Creatine Kinase-MB (CK-MB) (2024-2032) ($MN)
15 Global Heart Attack Diagnostics Market Outlook, By Myoglobin (2024-2032) ($MN)
16 Global Heart Attack Diagnostics Market Outlook, By C-Reactive Protein (CRP) (2024-2032) ($MN)
17 Global Heart Attack Diagnostics Market Outlook, By Brain Natriuretic Peptide (BNP) (2024-2032) ($MN)
18 Global Heart Attack Diagnostics Market Outlook, By Imaging Modality (2024-2032) ($MN)
19 Global Heart Attack Diagnostics Market Outlook, By Echocardiography (2024-2032) ($MN)
20 Global Heart Attack Diagnostics Market Outlook, By Computed Tomography (CT) (2024-2032) ($MN)
21 Global Heart Attack Diagnostics Market Outlook, By Magnetic Resonance Imaging (MRI) (2024-2032) ($MN)
22 Global Heart Attack Diagnostics Market Outlook, By Nuclear Imaging (2024-2032) ($MN)
23 Global Heart Attack Diagnostics Market Outlook, By X-ray (2024-2032) ($MN)
24 Global Heart Attack Diagnostics Market Outlook, By Diagnosis Method (2024-2032) ($MN)
25 Global Heart Attack Diagnostics Market Outlook, By Laboratory Testing (2024-2032) ($MN)
26 Global Heart Attack Diagnostics Market Outlook, By Imaging Testing (2024-2032) ($MN)
27 Global Heart Attack Diagnostics Market Outlook, By Point-of-Care Testing (2024-2032) ($MN)
28 Global Heart Attack Diagnostics Market Outlook, By Age Group (2024-2032) ($MN)
29 Global Heart Attack Diagnostics Market Outlook, By Below 40 Years (2024-2032) ($MN)
30 Global Heart Attack Diagnostics Market Outlook, By Above 60 Years (2024-2032) ($MN)
31 Global Heart Attack Diagnostics Market Outlook, By Application (2024-2032) ($MN)
32 Global Heart Attack Diagnostics Market Outlook, By Emergency Diagnosis (2024-2032) ($MN)
33 Global Heart Attack Diagnostics Market Outlook, By Risk Assessment (2024-2032) ($MN)
34 Global Heart Attack Diagnostics Market Outlook, By Therapy Monitoring (2024-2032) ($MN)
35 Global Heart Attack Diagnostics Market Outlook, By Research Applications (2024-2032) ($MN)
36 Global Heart Attack Diagnostics Market Outlook, By End User (2024-2032) ($MN)
37 Global Heart Attack Diagnostics Market Outlook, By Hospitals (2024-2032) ($MN)
38 Global Heart Attack Diagnostics Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
39 Global Heart Attack Diagnostics Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
40 Global Heart Attack Diagnostics Market Outlook, By Research Laboratories (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
